Cancer is a large group of diseases that can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, and go beyond their usual boundaries to invade adjoining parts of the body. According to the World Health Organization (WHO), it is the second most common cause of death globally, accounting for millions of deaths every year. Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervical and thyroid cancer are the most common among women. However, these are not necessarily the deadliest forms of cancer.

What makes cancer the deadliest depends upon how many people have it and what percentage of those people actually survive. Cancer researchers determine this on the basis of five-year relative survival. This is the percentage of people who are expected to survive the effects of a given cancer, excluding their risk of other possible causes of death, for five years past a diagnosis. It is also important to note that what makes cancer really deadly is that practically no cure for it. A cure for cancer would imply that there are no cancerous cells remaining in the body.

Here are the 5 deadliest cancers in the U.S., according to SEER five-year relative survival data for cases diagnosed between 2014 and 2020.

1. Pancreatic cancer occurs when cells in your pancreas, a gland in your abdomen that aids digestion, mutate and multiply out of control, forming a tumour. Major risk factors include smoking, obesity, diabetes, chronic pancreatitis, certain genetic mutations and environmental chemical exposure.

2. Esophageal cancer develops in the oesophagus, which is the tube that connects your throat to your stomach.

3. Liver cancer and intrahepatic bile duct cancer originate in the liver or bile ducts, often linked to hepatitis infections, heavy alcohol use, obesity, and aflatoxin exposure.

4. Lung and bronchus cancer primarily caused by smoking, secondhand smoke, and environmental pollutants, affects the lungs and airways, making it the leading cause of cancer death in the US.

5. Acute myeloid leukaemia (AML) is an aggressive blood and bone marrow cancer that progresses rapidly, often linked to genetic mutations, radiation exposure, and certain chemicals.

ALSO READ: Why Are Lifestyle Factors Making Millennials Vulnerable To Cancer?

In a major relief amid the ongoing Ebola outbreak, the World Health Organization (WHO) said the number of suspected cases has dropped to 116 after hundreds were ruled out following investigation.

Earlier, the number of suspected cases had neared 1,000 in the Democratic Republic of Congo (DRC).

The global health agency said on Tuesday that there had been 48 deaths and six recoveries in Congo, Reuters reported.

In Uganda, there have been nine confirmed cases and one associated death, WHO spokesperson Christian Lindmeier told reporters in Geneva.

Later, Uganda's Ministry of Health confirmed six additional Ebola cases, bringing the country's total number of confirmed infections to 15.

The ministry said in a statement on X that all six newly confirmed cases were among contacts of previously confirmed patients.

Hundreds Of Suspected Cases Ruled Out

Lindmeier explained that the latest figures were significantly lower because hundreds of suspected cases had been discounted after further investigation.

"They have been cleared out and have either other diseases or have just had a fever and nothing else," he said.

Lindmeier added that the numbers would continue to fluctuate as more people are tested.

A suspected case includes anyone identified through surveillance systems or presenting with symptoms at a health facility. Confirmed cases include only those who test positive for the Bundibugyo strain of Ebola.

Last week, the WHO reported 906 suspected Bundibugyo Ebola cases in Congo, including 223 suspected deaths under investigation.

Subsequently, Jean Kaseya, Director-General of the Africa Centres for Disease Control and Prevention, told the Financial Times that more than 1,100 suspected cases were being investigated.

Testing has posed a major challenge during the outbreak because the commonly used Ebola diagnostic tests initially failed to detect the Bundibugyo strain, for which there is currently no approved vaccine.

Meanwhile, the US Centers for Disease Control and Prevention (CDC) website also listed 116 suspected cases and noted: "On May 29, the DRC Ministry of Health updated their total suspect case count to remove suspected cases that have been ruled out after investigation and suspected deaths that are pending the results of ongoing investigation."

Kenyans Protest Proposed US Ebola Treatment Facility

Also read: Western Australia Records 22 Mpox Infections In 2026; Seven Reported Last Week

The United States' plan to establish an Ebola treatment facility in Kenya has sparked public concern about cross-border infection risks and triggered protests.

The proposed 50-bed isolation centre would be staffed by US medical personnel and is intended to treat US citizens affected by the Ebola outbreak in the Democratic Republic of Congo.

Asked about the proposal during a White House briefing, Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, said keeping affected Americans closer to the outbreak zone would help speed up treatment.

"You have a golden hour in many of these instances around trauma, but for illnesses, it’s also relatively short, so we are confident, and the State Department’s working on this diligently, that they are going to be able to work out something with Kenya. There has already been a fair amount of communication around this issue," Oz said.

Although Kenya has not recorded any Ebola cases, the proposed quarantine facility has raised fears among residents who believe it could increase the risk of exposure to the virus.

Prostate cancer is the most common cancer among men in the UK. The country records around 55,000 new prostate cancer cases and nearly 12,000 deaths every year.

Although the UK recently ruled out universal prostate cancer screening, opting instead for targeted screening of high-risk men, new cases continue to emerge every day. The latest high-profile figures diagnosed with the disease are former Liverpool winger John Barnes and comedian Bobby Davro.

John Barnes Calls Prostate Cancer A ‘Taboo Subject’

Barnes revealed that he had his prostate removed following a cancer diagnosis and described the condition as a "taboo subject" for men.

"Not many people know and it’s a bit of a taboo subject because we support women with breast cancer and it’s not even an issue," he told Times Radio.

Barnes stressed that "a lot of men don’t want to admit it or want to have it done because it makes them feel less than a man."

He added: "Men have to bite the bullet and swallow their pride and admit if they have problems."

Also read: Jill Biden Opens Up About Joe Biden’s Lifelong Cancer Battle

Bobby Davro Reveals Symptom Before Diagnosis

Meanwhile, 67-year-old Bobby Davro spoke on This Morning about his diagnosis, revealing that he had experienced erectile dysfunction beforehand.

Speaking on the ITV show, Davro said: "I think one in eight men get it. I think a lot of men of color, they get more prostate cancer, so it’s got to be checked.

"So go along and have your PSA (Prostate-Specific Antigen) checked, have the old prostate examined."

Davro continued: "He [the doctor] said: 'It’s a bit swollen, I think you should go and have a PSA test.' And it was 24, which wasn’t good at all."

"Not really. The only thing I had was erectile dysfunction. It wasn’t nice. I tried taking the blue pills. I realised something wasn’t quite right," he said about symptom before diagnosis.

Many other high-profile figures have been diagnosed with prostate cancer, including former UK Prime Minister David Cameron, BBC radio host Bob Harris, and six-time Olympic gold medalist Chris Hoy.

Despite the high burden of disease, the UK currently has no national prostate cancer screening program because of concerns over the accuracy of PSA tests. However, there has been growing pressure in recent years to introduce routine screening.

Read More: Benjamin Netanyahu Undergoes Treatment For Early-stage Prostate Cancer

What Do The New Guidelines Say?

After reviewing the latest evidence, the National Screening Committee (NSC) recommended against broad population-wide screening for prostate cancer.

The committee said the harms of screening outweigh the benefits for most groups. The final guidance states that routine screening should not be offered to:

• All men
• Black men, despite their risk being nearly double that of the general population
• Men with a family history of prostate cancer, as the disease is common enough that family history alone does not sufficiently narrow risk

Who Is Eligible For Targeted Screening?

Instead, the NSC recommends:

• Targeted prostate cancer screening involving PSA testing every two years for men aged 45 to 61
• Screening only for men who carry a pathogenic BRCA2 gene variant
• Screening for those who also have a family history of breast, ovarian, pancreatic, or prostate cancer

Symptoms To Watch For

The prostate is a small walnut-shaped gland in men that produces seminal fluid, which nourishes and transports sperm. Prostate cancer develops when abnormal cells begin growing in the gland.

Common symptoms include:

• Blood in the urine or semen
• Difficulty urinating
• Erectile dysfunction
• Reduced force in the urine stream
• Bone pain
• Unexplained weight loss.

Alkem Laboratories today announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths, with prices starting at Rs 350.

The company, in a statement, said it is the first in India to introduce semaglutide in a single-shot pre-filled syringe format for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.

Also Read: John Barnes, Bobby Davro Diagnosed With Prostate Cancer Even As UK Rules Out Universal Screening

The ready-to-use format will expand treatment options for patients while lowering entry barriers through affordable pricing.

“Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced,” said Dr. Vikas Gupta, Chief Executive Officer of Alkem Laboratories.

“In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy,” he added.

Alkem noted that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes.

Also read: India To Tighten Regulation For Semaglutide, Other GLP-1 Drugs

The launch follows Alkem’s introduction of semaglutide in pre-filled disposable and reusable injection pen formats in the Indian market in March 2026. The company has also secured regulatory approval for semaglutide vials, which it plans to launch soon.

Meanwhile, domestic peers such as Torrent Pharma and Dr Reddy’s have also introduced non-infringing tablets, with Lupin, Sun Pharma and several others expected to follow suit.

Semaglutide: Risks Vs Benefits

In people with type 2 diabetes, Harvard Health noted that the body's cells are resistant to the effects of insulin and the body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate the pancreas to release insulin and suppress the release of another hormone called glucagon.

These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.

Notably, semaglutide is not just a glucose-lowering drug, it improves weight and has proven cardiovascular, liver, and renal benefits.

Read More: Pairing Ozempic With Exercise Is Beneficial For Your Muscles, Study Finds

Wider availability could therefore help reduce long-term complications such as heart disease and kidney failure. If used appropriately, this could indeed be a major step forward in total metabolic care, the experts said.

“The increasing affordability of GLP-1 receptor agonists is a double-edged development. On one hand, it significantly improves access for patients with obesity, type 2 diabetes, and high cardiovascular risk, conditions that are highly prevalent in India. These drugs have demonstrated meaningful benefits in weight reduction, glycemic control, and even cardiovascular risk reduction, which could translate into long-term public health gains,” Dr Vivek Bindal, Senior Director & Head, Bariatric and Robotic Surgery, at Max Healthcare, told HealthandMe.